China Everbright Limited
Hong Kongeverbright.com
Overview
China Everbright Limited is a Hong Kong-based financial services company focused on asset management and investment, operating as a subsidiary of the state-owned China Everbright Group. The firm manages a variety of funds including private equity, venture capital, and sector-specific funds, investing in industries such as real estate, healthcare, new energy, infrastructure, and technology.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Kyinno Bio | Dec 2025 | Series B | Co-investor |
| The Lycra Company | Jun 2022 | Buyout/LBO | Co-investor |
| Gritgen Therapeutics | Mar 2022 | Series A | Co-investor |
| IASO BIO | Sep 2021 | Series C | Lead |
| Gritgen Therapeutics | Dec 2020 | Pre Seed | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.